COMMUNIQUÉS West-GlobeNewswire

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
20/11/2025
-- Evidence of Monotherapy Activity : Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd- [...]
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
20/11/2025
BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Keros Therapeutics Announces Final Results of Tender Offer
20/11/2025
LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to [...]
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference
20/11/2025
PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the [...]
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
20/11/2025
SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
20/11/2025
Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, [...]
PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025
20/11/2025
SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, [...]
Zevra Therapeutics, Inc. Announces CFO Transition
20/11/2025
CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
RxSight, Inc. to Present at the Piper Sandler Healthcare Conference
20/11/2025
ALISO VIEJO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – November 20, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following [...]
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
20/11/2025
CAREFNDR underscores the potential clinical value of p altusotine b eyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov. 20 [...]
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
20/11/2025
- Alpha DaRT pancreatic cancer p atient treatments underway in U.S. multi-center pilot study - - Newly received r adioactive m aterial l icense for New Hampshire f acility positions the Company for continued advancement [...]
CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference
20/11/2025
Company to participate in 1:1 Investor Meetings on December 4, 2025 SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
20/11/2025
CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
20/11/2025
BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of [...]
Informations sur le nombre total de droits de vote et d'actions
20/11/2025
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 20 novembre 2025, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]
Information on the total number of voting rights and shares
20/11/2025
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on [...]
Equillium to Participate in Upcoming Investor Conferences
20/11/2025
LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe [...]
Konica Minolta Healthcare Reinforces Leadership in Advanced Radiography with Seven Scientific Presentations on Dynamic Digital Radiography at RSNA 2025
20/11/2025
WAYNE, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., a leader in medical diagnostic imaging and healthcare information technology, is pleased to announce seven scientific [...]
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
20/11/2025
—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite [...]

Pages